Pershing Square's Bill Ackman says he'll show evidence that Herbalife is a massive fraud.
Bill Ackman, Pershing Square, explains why he is not upping his bid for Allergan. The market clearly thinks the chance of Valeant buying Allergan has gone up, says Ackman.
CNBC's Meg Tirrell reports Allergan posted Q2 results that beat on earnings and sales, as the company announced its restructuring plans, which may include an acquisition of its own.
Some of the names on the move ahead of the open.
Valeant has complained to regulators that claims made by Allergan to counter a hostile takeover are misleading, sources have told CNBC.
CNBC's Julia Boorstin provides insight to the reaction in shares of cable companies after a $80 billion takeover offer from 21st Century Fox for Time Warner was rejected.
CNBC's Andrew Ross Sorkin provides insight to the $80 billion takeover offer from 21st Century Fox for Time Warner, which was rejected.
CNBC's David Faber discusses Bill Ackman's backing of Valeant's takeover bid for Allergan. Allergan CEO David Pyott has bone to pick with Ackman.
CNBC's David Faber provides insight to AbbVie's $46 billion case to take over Shire.
British drug maker Shire has rejected a $46 billion takeover offer from U.S. based AbbVie. CNBC's Jim Cramer discusses the latest attempt by a U.S. health care company to tap into the low foreign tax rate.
Valeant says it will launch an exchange offer to Allergan shareholders, reports CNBC's Meg Tirrell.
Omar Ishrak, Medtronic chairman & CEO, discusses the state of the health care industry and explains the extensive M&A activity happening in the sector.
FMHR trader Pete Najarian takes a close look at unusual activity in options for Hillshire Brands, and the action in its stock as takeover talks continue.
Pilgrim's Pride is sweetening its takeover offer for Hillshire Brands. CNBC's Jim Cramer and David Faber discuss the "insane" bidding for Hillshire.
Mario Gabelli, Gamco Investors chairman & CEO, shares his thoughts on how to play the social media, e-commerce, and natural gas space.
Mario Gabelli, Gamco Investors chairman & CEO, explains why he is watching shares of Protective Life, Interpublic Group, and Hillshire Brands.
Tyson Foods is jumping in the takeover battle for Hillshire. The "Squawk on the Street" news team discuss Tyson's $50 a share offer.
This year has been the year of mergers, acquisitions and hostile takeovers. Attorney Frank Aquila, Sullivan & Cromwell, discusses what's behind the recent M&A boom.
The "Squawk on the Street" take a close look at the offer from Pilgrim's Pride for Hillshire Brands. Pilgrim's Pride wants Hillshire to drop Pinnacle Foods of which Birds Eye Foods is a brand.
CNBC's David Faber and Jim Cramer discuss the latest M&A action, including Valeant Pharmaceuticals raising its takeover bid for Allergan, and GE improving its offer for France's Alstom.